According to researchers, only 3 studies have previously explored a potential link between AD and dementia with inconsistent findings.
This article was originally published on Dermatology Times®. It has been lightly edited.
Atopic dermatitis (AD) and systemic inflammation are not linked to a risk of dementia, according to a recent study published in the Journal of the European Academy of Dermatology and Venereology Clinical Practice.
Researchers involved in the study noted that inflammation, including inflammation caused by AD, has been previously linked to the development of other chronic diseases, and systemic inflammation may trigger nervous system inflammation—an important step in the development of dementia. However, they noted that only 3 prior studies have explored a potential link between inflammatory AD, erythrocyte sedimentation rate (ESR), and a risk of dementia.
Researchers used data from a Swedish register, which includes all individuals who had lived in Sweden between 1990 and 2018, to establish 3 exploratory cohort groups.
Cohort 1 consisted of men (n = 795,680) who were born between 1951 and 1968, all of whom had underwent a conscription examination at 18 years old, receiving diagnoses confirmed by a clinician or medical records. Due to discontinuance of the measurement of ESR during these examinations, researchers analyzed a subgroup of this population: those who were born up to the year 1966.
Cohort 2 (n = 1,757,600) consisted of all members of cohort 1—this time, including any men and women who were born during the same time period who had not undergone a conscription examination. Cohort 3 (n = 3,988,783) consisted of all members of cohorts 1 and 2, additionally including any individuals born between 1930 and 1950. Due to a lack of conscription examination participation in a portion of these patient cohorts, researchers utilized inpatient and outpatient records from the National Patient Register (NPR) to source for AD diagnoses.
Researchers also used the NPR to determine time of onset of dementia, or the Cause of Death Register (CDR) to determine whether dementia was a contributory cause of death in patients. Time of onset was established as 3 years before NPR diagnosis and 5 years prior to CDR-recorded death.
Woman scratching her atopic dermatitis | Image credit: Monstar Studio - stock.adobe.com
Among members of cohort 1, the rate of dementia for individuals without AD was 21.7 per 100,000 person-years. For those with AD, the rate of dementia was 13.1 per 100,000 person-years. This risk was nonsignificantly lower for those with AD.
Among members of cohort 2, the rate of dementia among those without AD was 23.7 per 100,000 person-years and 21.9 per 100,000 for those with AD. Researchers observed no significant difference in risk of dementia among status of AD diagnosis.
In cohort 3, individuals with an AD diagnosis had an observable significantly lower risk of dementia (77.0 per 100,000 person-years) than those without AD (181.2 per 100,000 person-years).
“The results of this study do not support the hypotheses that systemic inflammation measured by ESR in late adolescence or AD diagnosed at any point in life are associated with higher risk of dementia,” the authors wrote.
Reference
Vingeliene S, Hiyoshi A, Carlberg M, et al. Atopic dermatitis, systemic inflammation and subsequent dementia risk. JEADV Clin Pract. doi:10.1002/jvc2.249
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More